Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AUROVELA FE 1.5/30 vs ALTAVERA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination oral contraceptive containing norethindrone acetate and ethinyl estradiol. Norethindrone acetate is a progestin that suppresses gonadotropin release, inhibiting ovulation; ethinyl estradiol is an estrogen that provides feedback inhibition of follicle-stimulating hormone (FSH) and luteinizing hormone (LH), preventing follicular development and ovulation. Additionally, it causes changes in cervical mucus (increased viscosity) and endometrium (reduced receptivity).
Combination of ethinyl estradiol and desogestrel: ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; desogestrel (progestin) causes cervical mucus thickening and endometrial atrophy, preventing implantation.
Prevention of pregnancy (FDA-approved),Treatment of moderate acne vulgaris in females at least 15 years of age who have no known contraindications to oral contraceptive therapy and have achieved menarche (off-label but common use),Management of menstrual disorders (off-label): dysmenorrhea, menorrhagia, irregular bleeding,Hormonal contraception in patients with iron deficiency anemia (due to iron supplementation in formulation)
Prevention of pregnancy,Treatment of moderate acne vulgaris (in females ≥15 years with no contraindications)
One tablet orally once daily at the same time each day for 28 consecutive days.
1 tablet (ethinyl estradiol 0.03 mg / levonorgestrel 0.15 mg) orally once daily for 21 days, followed by 7 placebo days.
Norethindrone: 5-14 hours (terminal); Ethinyl estradiol: 10-20 hours (terminal). Steady-state achieved within 5-7 days; contraceptive efficacy maintained with daily dosing.
Levonorgestrel: terminal elimination half-life 25±10 hours; ethinyl estradiol: 13±7 hours. Clinical context: steady-state concentrations achieved within 5-7 days; contraceptive efficacy requires consistent daily dosing.
Norethindrone acetate is metabolized primarily in the liver via reduction and conjugation (sulfation and glucuronidation). It is a prodrug, rapidly hydrolyzed to norethindrone. Ethinyl estradiol is metabolized via CYP3A4 in the liver, undergoing hydroxylation, methylation, and conjugation (glucuronidation and sulfation). Both undergo enterohepatic recirculation.
Ethinyl estradiol: primarily metabolized by CYP3A4; undergoes sulfation and glucuronidation. Desogestrel: rapidly converted to active metabolite etonogestrel via CYP2C9 and CYP2C19; further metabolism by CYP3A4.
Renal: ~50-60% as metabolites, <10% unchanged; Fecal: ~40-50% via bile; Ethinyl estradiol undergoes enterohepatic recirculation.
Renal excretion of metabolites and unchanged drug: ~30% (levonorgestrel) and ~20% (ethinyl estradiol) in urine; biliary/fecal elimination: ~40-50% as conjugates and metabolites.
Norethindrone: ~97% (albumin and SHBG); Ethinyl estradiol: ~97-98% (albumin, not SHBG).
Levonorgestrel: 98-99% bound to sex hormone-binding globulin (SHBG) and albumin; ethinyl estradiol: 98% bound to albumin.
Norethindrone: 2-5 L/kg (extensive tissue distribution); Ethinyl estradiol: 2-4 L/kg (distributes into breast milk and body fat).
Levonorgestrel: Vd ~1.8 L/kg (suggesting extensive tissue distribution). Ethinyl estradiol: Vd ~2.4 L/kg.
Oral: Norethindrone ~64% (first-pass effect); Ethinyl estradiol ~40-45% (extensive first-pass metabolism).
Oral bioavailability: levonorgestrel ~100% (nearly complete); ethinyl estradiol ~45-50% (first-pass hepatic metabolism).
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (GFR <30 m L/min/1.73 m²); use is not recommended.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal disease or acute renal failure due to potential fluid retention.
Contraindicated in severe hepatic disease (Child-Pugh class C). Use with caution and monitor liver function in mild to moderate impairment (Child-Pugh A/B); consider alternative methods if liver function deteriorates.
Contraindicated in severe hepatic dysfunction (Child-Pugh class B or C). Use caution in mild to moderate impairment (Child-Pugh A); monitor liver enzymes.
Not indicated for use before menarche.
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults (1 tablet daily, 21/7 regimen) after evaluation of risks.
Not indicated for use in postmenopausal women. No specific studies in elderly; consider age-related risks of thromboembolism and cardiovascular disease.
Not indicated for postmenopausal women. No specific geriatric dosing; consider increased risk of thromboembolism, cardiovascular disease, and metabolic effects in older women of reproductive age.
WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS. Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive use. This risk increases with age, especially in women over 35 years of age, and with the number of cigarettes smoked. Women who use combination oral contraceptives should be strongly advised not to smoke.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives. Risk increases with age (especially >35 years) and with number of cigarettes smoked. Women who use combined hormonal contraceptives should be strongly advised not to smoke.
Thrombotic disorders: risk of venous thromboembolism, arterial thromboembolism, stroke, myocardial infarction; increased in smokers, obese, or those with thrombogenic mutations,Hepatic neoplasia: rare cases of benign and malignant liver tumors reported,Ocular effects: retinal thrombosis, papilledema, optic neuritis,Cardiovascular: hypertension, lipid effects, increased risk in women with hypertension or hyperlipidemia,Carbohydrate metabolism: impaired glucose tolerance, increased insulin resistance,Headache/migraine: discontinue if new or worsening migraine or severe headache,Bleeding irregularities: breakthrough bleeding, spotting, amenorrhea,Gallbladder disease: increased risk,Depression: can exacerbate,Hereditary angioedema: may trigger or worsen,Chloasma: may cause melasma, exacerbated by sun exposure,Iron supplementation: caution in hemochromatosis or iron overload disorders,Dental/gingival: gingivitis,Laboratory tests: may affect thyroid, sex hormone-binding globulin, coagulation factors
Thrombotic disorders: risk of venous thromboembolism (VTE), stroke, myocardial infarction; discontinue if thrombotic event occurs.,Hepatic disease: discontinue if jaundice or liver function abnormalities develop.,Hypertension: monitor blood pressure; discontinue if uncontrolled.,Carbohydrate metabolism: may affect glucose tolerance; monitor diabetic patients.,Depression: discontinue if significant depression occurs.,Gallbladder disease: increased risk of cholelithiasis.
Current or past history of thrombophlebitis or venous thromboembolism,Cerebrovascular or coronary artery disease (current or history),Known or suspected pregnancy,Undiagnosed abnormal uterine bleeding,Known or suspected estrogen-dependent neoplasia (e.g., breast cancer, endometrial cancer),Active liver disease, impaired liver function, or benign/malignant liver tumors (current or history),Hypersensitivity to any component of the product,Women over 35 years of age who smoke cigarettes,Uncontrolled hypertension (blood pressure >160/100 mm Hg),Migraine with aura at any age,Diabetes mellitus with vascular involvement,Major surgery with prolonged immobilization,Current or history of breast cancer (confirmed or suspected)
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast carcinoma,Estrogen-dependent neoplasia (known or suspected),Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma (known or suspected),Pregnancy (known or suspected),Hypersensitivity to any component
Grapefruit and grapefruit juice may increase ethinyl estradiol levels; avoid large quantities. No other significant food interactions. Take with food or milk to reduce gastrointestinal upset if needed.
No significant food interactions. Alcohol does not affect efficacy but may increase risk of adverse effects such as nausea. Grapefruit juice has no known interaction. Avoid excessive alcohol consumption due to potential hepatotoxicity.
Contraindicated in pregnancy. Use during first trimester associated with oral clefts and cardiac defects; second and third trimester exposure linked to feminization of male fetuses and other anomalies due to progestin effects. Increased risk of ectopic pregnancy. On-label indications exclude pregnancy use.
ALTAVERA contains ethinyl estradiol and levonorgestrel. First trimester: Inadvertent exposure during organogenesis is associated with a very low absolute risk of cardiovascular defects (relative risk 1.2-1.4) and no consistent increase in other major malformations. Second and third trimesters: No known teratogenic effects, but theoretical risks from estrogenic effects (e.g., feminization of male fetus). Postnatal: No increased risk of long-term developmental effects from pregnancy exposure.
Excreted in breast milk; M/P ratio unknown. May reduce milk production and alter composition. Use only if benefits outweigh risks, with monitoring for infant jaundice and weight gain. Consider alternative contraception during breastfeeding.
Combined oral contraceptives may reduce milk production and quality, especially in early lactation. Ethinyl estradiol transfers into breast milk at low levels (M/P ratio approximately 0.1-0.2), excluding clinical effects in term infants. Levonorgestrel transfer is minimal (M/P ratio ~0.2-0.4). Use is generally avoided in breastfeeding women, especially during the first 6 weeks postpartum. Progestin-only methods are preferred.
Not applicable; drug is contraindicated in pregnancy. No dose adjustments recommended as therapy should be discontinued immediately if pregnancy occurs.
Contraindicated in pregnancy. No dose adjustment recommended because use is discontinued upon confirmed or suspected pregnancy. Pharmacokinetic changes in pregnancy (e.g., increased hepatic clearance, altered binding proteins) are not relevant for this indication.
AUROVELA FE 1.5/30 is a combined oral contraceptive containing norethindrone acetate 1.5 mg and ethinyl estradiol 30 mcg. It contains ferrous fumarate as an iron supplement in the placebo pills. Patients with a history of venous thromboembolism, thrombogenic mutations, or estrogen-sensitive malignancies should not use this medication. Baseline blood pressure, lipid profile, and liver function tests are recommended. Counsel patients to take at the same time daily to maintain efficacy. Consider drug interactions with antibiotics, anticonvulsants, and St. John's Wort which may reduce contraceptive effectiveness.
ALTAVERA is a combined oral contraceptive (COC) containing ethinylestradiol and levonorgestrel. It inhibits ovulation via suppression of gonadotropins. Counsel patients to take at the same time daily to maintain efficacy. Missed pill management: if missed within 12 hours, take immediately; if >12 hours, take last missed pill and use backup contraception for 7 days. Be aware of increased VTE risk, especially in smokers over 35. May reduce effectiveness of lamotrigine; monitor seizure control. Initiate on the first day of menses or first Sunday after onset.
Take one tablet daily at the same time each day, with or without food.,Swallow tablets whole; do not crush or chew.,Missed dose management: if missed by less than 12 hours, take it as soon as remembered; if more than 12 hours, skip the missed dose and continue with next tablet; use back-up contraception if multiple doses missed.,Common side effects include nausea, breast tenderness, weight changes, and breakthrough bleeding; these may improve after 2-3 cycles.,Seek immediate medical attention if you experience leg pain/swelling, chest pain, shortness of breath, severe headache, vision changes, or jaundice.,Does not protect against sexually transmitted infections (STIs); use condoms for STI prevention.,Inform your healthcare provider of all medications, including over-the-counter drugs and herbal supplements.,Continue taking the iron-containing placebo tablets during the placebo week; do not skip.
Take one tablet daily at the same time each day, with or without food.,If you miss a pill by less than 12 hours, take it as soon as you remember. If more than 12 hours, take the missed pill and use a backup method (e.g., condoms) for the next 7 days.,Smoking increases your risk of serious cardiovascular side effects, especially if you are over 35 years old. Do not smoke while taking this medication.,Seek immediate medical attention if you experience sudden severe headache, chest pain, leg pain/swelling, or vision changes (symptoms of blood clots).,This medication does not protect against HIV or other sexually transmitted infections.,If you are taking lamotrigine or other anticonvulsants, tell your doctor; your seizure medication may be less effective.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AUROVELA FE 1.5/30 vs ALTAVERA, answered by our medical review team.
AUROVELA FE 1.5/30 is a Oral Contraceptive that works by Combination oral contraceptive containing norethindrone acetate and ethinyl estradiol. Norethindrone acetate is a progestin that suppresses gonadotropin release, inhibiting ovulation; ethinyl estradiol is an estrogen that provides feedback inhibition of follicle-stimulating hormone (FSH) and luteinizing hormone (LH), preventing follicular development and ovulation. Additionally, it causes changes in cervical mucus (increased viscosity) and endometrium (reduced receptivity).. ALTAVERA is a Combined Oral Contraceptive that works by Combination of ethinyl estradiol and desogestrel: ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; desogestrel (progestin) causes cervical mucus thickening and endometrial atrophy, preventing implantation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AUROVELA FE 1.5/30 and ALTAVERA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AUROVELA FE 1.5/30 is: One tablet orally once daily at the same time each day for 28 consecutive days.. The standard adult dose of ALTAVERA is: 1 tablet (ethinyl estradiol 0.03 mg / levonorgestrel 0.15 mg) orally once daily for 21 days, followed by 7 placebo days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AUROVELA FE 1.5/30 and ALTAVERA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AUROVELA FE 1.5/30 is classified as Category C. Contraindicated in pregnancy. Use during first trimester associated with oral clefts and cardiac defects; second and third trimester exposure linked to feminization of male fetuses. ALTAVERA is classified as Category C. ALTAVERA contains ethinyl estradiol and levonorgestrel. First trimester: Inadvertent exposure during organogenesis is associated with a very low absolute risk of cardiovascular def. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.